Processa Pharmaceuticals issues stockholder letter, files 8-K with SEC
Processa Pharmaceuticals, Inc. (PCSA) recently sent a letter to its stockholders and submitted an 8-K filing with the Securities and Exchange Commission. This announcement did not provide further specifics on the letter's content. The stock's current price is $1.94, significantly lower than its 52-week high of $8.99, a 77% decline this year.
However, in the last month, the stock has rebounded, showing a strong return. InvestingPro data indicates the stock may currently be undervalued, with a FAIR overall financial health rating. Investors can access 6 additional InvestingPro Tips and comprehensive metrics for more detailed analysis. The company is based in Delaware and trades under the ticker symbol PCSA on The Nasdaq Stock Market LLC.
The filing was signed by Russell Skibsted, the company's Chief Financial Officer. The 2026 Annual Meeting of Shareholders recently took place, where several proposals were approved, including amending the 2019 Omnibus Incentive Plan. Shareholders voted overwhelmingly in favor of this amendment.
Written by urgent.news from Investing.com's reporting — not their text. Machine-written — may contain errors; check the original before relying on it.
This story
This is one outlet's version. Read the fullest account.
